Published in J Subst Abuse Treat on October 27, 2011
Hepatitis C virus control among persons who inject drugs requires overcoming barriers to care. World J Gastroenterol (2013) 0.93
Missed opportunities for hepatitis C testing in opioid treatment programs. Am J Public Health (2013) 0.93
Cost-effectiveness of rapid hepatitis C virus (HCV) testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programs. Addiction (2015) 0.92
Hepatitis C virus-related knowledge and willingness to receive treatment among patients on methadone maintenance. J Addict Med (2014) 0.81
Determinants of the availability of hepatitis C testing services in opioid treatment programs: results from a national study. Am J Public Health (2014) 0.81
A qualitative analysis of provider barriers and solutions to HIV testing for substance users in a small, largely rural southern state. J Rural Health (2013) 0.79
The impact of lifetime drug use on hepatitis C treatment outcomes in insured members of an integrated health care plan. Drug Alcohol Depend (2013) 0.76
Willingness to Receive Treatment for Hepatitis C among Injecting Drug Users on Methadone Program: Implications for Education and Treatment. Addict Health (2016) 0.75
Does the Strategy of Risk Group Testing for Hepatitis C Hit the Target? Front Pharmacol (2017) 0.75
Medical and Behavioral Approaches to Engage People Who Inject Drugs Into Care for Hepatitis C Virus Infection. Addict Disord Their Treat (2017) 0.75
The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med (2006) 18.63
Global epidemiology of hepatitis C virus infection. Lancet Infect Dis (2005) 16.44
Chronic hepatitis B. Hepatology (2007) 13.75
Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR Recomm Rep (1998) 12.78
Diagnosis, management, and treatment of hepatitis C. Hepatology (2004) 11.62
Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med (1998) 5.90
A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep (2006) 5.63
National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002--June 10-12, 2002. Hepatology (2002) 5.16
Viral hepatitis B. Lancet (2003) 4.86
Global epidemiology of hepatitis B virus. J Clin Gastroenterol (2004) 4.48
Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol (2004) 4.12
Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994. Am J Public Health (1999) 3.55
Drug abuse treatment as an HIV prevention strategy: a review. Drug Alcohol Depend (2000) 3.18
Overview of 5-year followup outcomes in the drug abuse treatment outcome studies (DATOS). J Subst Abuse Treat (2003) 2.93
Prevention of hepatitis A with the hepatitis A vaccine. N Engl J Med (2004) 2.87
Prevention of hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep (1999) 2.82
Drug abuse treatment as AIDS prevention. Public Health Rep (1998) 2.80
Factors associated with fulminant liver failure during an outbreak among injection drug users with acute hepatitis B. Hepatology (2004) 2.78
A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer (1998) 2.64
Hepatitis C among noninjecting drug users: a report. Subst Use Misuse (2001) 2.12
Incidence and risk factors for acute hepatitis B in the United States, 1982-1998: implications for vaccination programs. J Infect Dis (2002) 2.06
Characteristics of substance abuse treatment programs providing services for HIV/AIDS, hepatitis C virus infection, and sexually transmitted infections: the National Drug Abuse Treatment Clinical Trials Network. J Subst Abuse Treat (2006) 1.81
A meta-analysis of case-control studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma in China. Br J Cancer (2005) 1.76
Role of drug-abuse treatment in limiting the spread of AIDS. Rev Infect Dis (1988) 1.76
Review article: hepatitis vaccination in patients with chronic liver disease. Aliment Pharmacol Ther (2004) 1.68
Sharing of noninjection drug-use implements as a risk factor for hepatitis C. Subst Use Misuse (2004) 1.61
Age-specific seroprevalence of HIV, hepatitis B virus, and hepatitis C virus infection among injection drug users admitted to drug treatment in 6 US cities. Am J Public Health (2002) 1.61
Clinical practice: prevention of hepatitis B with the hepatitis B vaccine. N Engl J Med (2004) 1.59
Acute hepatitis A and B in patients with chronic liver disease: prevention through vaccination. Am J Med (2005) 1.30
Health services for HIV/AIDS, HCV, and sexually transmitted infections in substance abuse treatment programs. Public Health Rep (2007) 1.29
Guidelines for the control of hepatitis A virus infection. Commun Dis Public Health (2001) 1.24
Risks associated with hepatitis A and hepatitis B in patients with hepatitis C. J Clin Gastroenterol (2001) 1.20
Factors associated with hepatitis C virus infection in injection and noninjection drug users in Italy. Clin Infect Dis (2003) 1.18
Evaluating existing recommendations for hepatitis A and B vaccination. Am J Med (2005) 1.15
Fulminant hepatitis A in intravenous drug users with chronic liver disease. Ann Intern Med (1989) 1.09
HAV infection in chronic liver disease: a rationale for vaccination. Vaccine (2003) 1.06
An outbreak of hepatitis A virus infection with a high case-fatality rate among injecting drug users. J Hepatol (2005) 0.99
Epidemiology and natural history of hepatitis C virus infection in injection drug users: implications for treatment. Clin Infect Dis (2005) 0.97
Hepatitis C virus infection among noninjecting drug users in New York City. J Med Virol (2003) 0.96
An outbreak of hepatitis A amongst injecting drug users. Epidemiol Infect (2001) 0.92
A comparison of HCV antibody testing in drug-free and methadone maintenance treatment programs in the United States. Drug Alcohol Depend (2004) 0.91
Public health perspective on vaccine-preventable hepatitis: integrating hepatitis A and B vaccines into public health settings. Am J Med (2005) 0.89
Hepatitis vaccination among drug users. Vaccine (2006) 0.88
The importance and benefits of hepatitis A prevention in chronic liver disease patients. J Gastroenterol Hepatol (2004) 0.86
Viral hepatitis and liver transplantation. Semin Liver Dis (2006) 0.85
A high-resolution map of human evolutionary constraint using 29 mammals. Nature (2011) 8.67
Cingulate-precuneus interactions: a new locus of dysfunction in adult attention-deficit/hyperactivity disorder. Biol Psychiatry (2007) 4.98
Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J Am Acad Child Adolesc Psychiatry (2008) 3.52
Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience. Am J Addict (2004) 2.85
Effectiveness of HIV/STD sexual risk reduction groups for women in substance abuse treatment programs: results of NIDA Clinical Trials Network Trial. J Acquir Immune Defic Syndr (2008) 2.78
Network homogeneity reveals decreased integrity of default-mode network in ADHD. J Neurosci Methods (2007) 2.56
Training and fidelity monitoring of behavioral interventions in multi-site addictions research. Drug Alcohol Depend (2006) 2.24
Commitment to assessment and treatment: comprehensive care for patients gravely disabled by alcohol use disorders. Lancet (2013) 2.12
Characteristics of substance abuse treatment programs providing services for HIV/AIDS, hepatitis C virus infection, and sexually transmitted infections: the National Drug Abuse Treatment Clinical Trials Network. J Subst Abuse Treat (2006) 1.81
Comorbid conditions, treatment, and health maintenance in older persons with human immunodeficiency virus infection in New York City. Clin Infect Dis (2002) 1.73
Smoking cessation treatment in community-based substance abuse rehabilitation programs. J Subst Abuse Treat (2007) 1.57
Reduced interhemispheric resting state functional connectivity in cocaine addiction. Biol Psychiatry (2011) 1.45
Health services for HIV/AIDS, HCV, and sexually transmitted infections in substance abuse treatment programs. Public Health Rep (2007) 1.29
Multisite effectiveness trials of treatments for substance abuse and co-occurring problems: have we chosen the best designs? J Subst Abuse Treat (2010) 1.21
The New York policy on smoking in addiction treatment: findings after 1 year. Am J Public Health (2012) 1.19
Impact of an educational program on efficacy and adherence with a twice-daily lamivudine/zidovudine/abacavir regimen in underrepresented HIV-infected patients. J Acquir Immune Defic Syndr (2003) 1.18
Predictors of outcome for short-term medically supervised opioid withdrawal during a randomized, multicenter trial of buprenorphine-naloxone and clonidine in the NIDA clinical trials network drug and alcohol dependence. Drug Alcohol Depend (2008) 1.07
Protection against puromycin aminonucleoside-induced chronic renal disease in the Wistar-Furth rat. Am J Physiol Renal Physiol (2004) 1.04
Extended-release naltrexone for treatment of alcohol dependence in primary care. J Subst Abuse Treat (2010) 1.03
Measuring outcome in cocaine clinical trials: a comparison of sweat patches with urine toxicology and participant self-report. Addiction (2003) 1.03
States and substance abuse treatment programs: funding and guidelines for infection-related services. Am J Public Health (2008) 1.01
Cognitive performance in schizophrenia: relationship to regional brain volumes and psychiatric symptoms. Psychiatry Res (2002) 1.01
Implementation of a Smoking Cessation Treatment Study at Substance Abuse Rehabilitation Programs: Smoking Behavior and Treatment Feasibility Across Varied Community-based Outpatient Programs. J Addict Med (2007) 0.99
A randomized controlled study of a web-based performance improvement system for substance abuse treatment providers. J Subst Abuse Treat (2010) 0.98
Pharmacokinetics and pharmacodynamics of multiple sublingual buprenorphine tablets in dose-escalation trials. J Clin Pharmacol (2006) 0.96
Renal cortex neuronal nitric oxide synthase in response to rapamycin in kidney transplantation. Nitric Oxide (2007) 0.95
Retrospective analyses of pooled data from CREST I and CREST II trials for treatment of cocaine dependence. Addiction (2005) 0.95
Barriers to providing health services for HIV/AIDS, hepatitis C virus infection and sexually transmitted infections in substance abuse treatment programs in the United States. J Addict Dis (2011) 0.95
The relationship between depression and smoking cessation outcomes in treatment-seeking substance abusers. Am J Addict (2010) 0.94
Hepatitis C virus control among persons who inject drugs requires overcoming barriers to care. World J Gastroenterol (2013) 0.93
Buprenorphine-naloxone maintenance following release from jail. Subst Abus (2012) 0.92
Extended-release naltrexone plus medical management alcohol treatment in primary care: findings at 15 months. J Subst Abuse Treat (2012) 0.91
Prenatal protein deprivation alters dopamine-mediated behaviors and dopaminergic and glutamatergic receptor binding. Brain Res (2008) 0.90
Relation of neurological soft signs to psychiatric symptoms in schizophrenia. Schizophr Res (2007) 0.90
Nefazodone treatment of cocaine dependence with comorbid depressive symptoms. Addiction (2005) 0.89
A feasibility study of a web-based performance improvement system for substance abuse treatment providers. J Subst Abuse Treat (2007) 0.89
A preliminary study of the effects of individual patient-level feedback in outpatient substance abuse treatment programs. J Subst Abuse Treat (2011) 0.87
Is HIV infection a risk factor for complications of surgery? Mt Sinai J Med (2002) 0.87
Disparities in Health Services for HIV/AIDS, Hepatitis C Virus, and Sexually Transmitted Infections: Role of Substance Abuse Treatment Programs. J Addict Med (2009) 0.87
Outcomes among buprenorphine-naloxone primary care patients after Hurricane Sandy. Addict Sci Clin Pract (2014) 0.87
Drug addiction and stress-response genetic variability: association study in African Americans. Ann Hum Genet (2014) 0.87
Prepulse inhibition of acoustic startle in subjects with schizophrenia treated with olanzapine or haloperidol. Psychiatry Res (2003) 0.86
Substance abuse treatment clinician opinions and infectious disease service delivery. J Addict Dis (2009) 0.86
Substance-use screening and interventions in dental practices: survey of practice-based research network dentists regarding current practices, policies and barriers. J Am Dent Assoc (2013) 0.86
Repetitive-sequence-based PCR using the DiversiLab system for identification of Aspergillus species. J Clin Microbiol (2008) 0.85
Reimbursing dentists for smoking cessation treatment: views from dental insurers. Nicotine Tob Res (2012) 0.85
A placebo-controlled screening trial of olanzapine, valproate, and coenzyme Q10/L-carnitine for the treatment of cocaine dependence. Addiction (2005) 0.83
AIDS research in the NIDA Clinical Trials Network: emerging results. Drug Alcohol Depend (2007) 0.83
Screening and imputed prevalence of ADHD in adult patients with comorbid substance use disorder at a residential treatment facility. Postgrad Med (2009) 0.83
Effects of regulation on methadone and buprenorphine provision in the wake of Hurricane Sandy. J Urban Health (2014) 0.83
Alcohol education provided to opioid treatment program patients: results of a nationwide survey. J Drug Educ (2010) 0.82
Program, counselor, and patient variability in the alliance: a multilevel study of the alliance in relation to substance use outcomes. J Subst Abuse Treat (2011) 0.82
A placebo controlled, double-blind study of mecamylamine treatment for cocaine dependence in patients enrolled in an opiate replacement program. Subst Abus (2005) 0.81
Hepatitis C virus-related knowledge and willingness to receive treatment among patients on methadone maintenance. J Addict Med (2014) 0.81
Electronic health information system at an opioid treatment programme: roadblocks to implementation. J Eval Clin Pract (2011) 0.81
Medication status affects the relationship of symptoms to prepulse inhibition of acoustic startle in schizophrenia. Psychiatry Res (2006) 0.81
Dopaminergic pathway polymorphisms and heroin addiction: further support for association of CSNK1E variants. Pharmacogenomics (2014) 0.81
Daily versus thrice-weekly interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected persons: a multicenter randomized controlled trial. J Acquir Immune Defic Syndr (2004) 0.81
Overlapping dopaminergic pathway genetic susceptibility to heroin and cocaine addictions in African Americans. Ann Hum Genet (2015) 0.80
Longitudinal trends in antibiotic resistance in US nursing homes, 2000-2004. Infect Control Hosp Epidemiol (2007) 0.80
Smoking cessation treatment among patients in community-based substance abuse rehabilitation programs: exploring predictors of outcome as clues toward treatment improvement. Am J Drug Alcohol Abuse (2011) 0.80
Variation among state-level approaches to addressing alcohol abuse in opioid treatment programs. J Subst Abuse Treat (2010) 0.80
Researcher experiences with IRBs: a survey of members of the American College of Neuropsychopharmacology. IRB (2011) 0.79
Sleep and daytime sleepiness of patients with left ventricular assist devices: a longitudinal pilot study. Prog Transplant (2011) 0.79
Quantitative electroencephalographic studies of cue-induced cocaine craving. Clin Electroencephalogr (2003) 0.79
"What made me stay?" A review of the reasons student nurses enrolled in a Bachelor of Nursing programme completed their studies: a descriptive phenomenological study. Nurse Educ Today (2012) 0.78
Treatment predictors of extrapyramidal side effects in patients with tardive dyskinesia: results from Veterans Affairs Cooperative Study 394. J Clin Psychopharmacol (2002) 0.78
NIDA's Clinical Trials Network: an opportunity for HIV research in community substance abuse treatment programs. Am J Drug Alcohol Abuse (2011) 0.78
Safety, efficacy, and tolerability of nelfinavir-containing antiretroviral therapy for patients coinfected with HIV and hepatitis C undergoing methadone maintenance. J Subst Abuse Treat (2006) 0.77
Opioid-like effects of the neurokinin 1 antagonist aprepitant in patients maintained on and briefly withdrawn from methadone. Am J Drug Alcohol Abuse (2013) 0.76
Diurnal variation in plasma homovanillic acid in patients with schizophrenia and healthy controls. Schizophr Res (2005) 0.76
Improvements in HCV-related Knowledge Among Substance Users on Opioid Agonist Therapy After an Educational Intervention. J Addict Med (2016) 0.76
Clinical pharmacist intervention for patients with left ventricular assist devices. Ann Pharmacother (2011) 0.76
Psychiatric comorbidity, red flag behaviors, and associated outcomes among office-based buprenorphine patients following Hurricane Sandy. J Urban Health (2014) 0.75
Substance abuse treatment as HIV prevention: more questions than answers. J Natl Med Assoc (2010) 0.75
Electronic medical record system at an opioid agonist treatment programme: study design, pre-implementation results and post-implementation trends. J Eval Clin Pract (2011) 0.75
Evaluation of an electronic medical record system at an opioid agonist treatment program. J Addict Med (2014) 0.75
Care for patients with grave alcohol use disorders - Authors' reply. Lancet (2013) 0.75
Medical and Mental Health Status Among Drug Dependent Patients Participating in a Smoking Cessation Treatment Study. J Drug Issues (2009) 0.75
A bounding estimate of neutron dose based on measured photon dose around single pass reactors at the Hanford site. Health Phys (2010) 0.75